Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306822 | 0.75 | FFAR4 (0.55) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL29788132 | 0.75 | FFAR4 (0.55) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL5540237 | 0.75 | SCN9A (0.44) | SCN9ATRPA1ALDH1A1FFAR4HSD11B1 | |
| SCHEMBL7701143 | 0.74 | ALDH1A1 (0.50) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL699801 | 0.73 | FFAR4 (0.47) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL3543334 | 0.72 | SCN9A (0.46) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL456578 | 0.71 | SCN9A (0.48) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL1045874 | 0.70 | FFAR4 (0.51) | SCN9ATRPA1L3MBTL1ALDH1A1FFAR4 | |
| SCHEMBL5541261 | 0.70 | ALDH1A1 (0.42) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2123079 | 0.70 | CNR2 (0.44) | SCN9ATRPA1L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SCN9A 3612/4885TRPA1 3038/4885L3MBTL1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.